Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556918 · ClinicalTrials.gov registry record · Phase 4
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
A Phase 4 study of Hyperglycemia, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 202
- Enrollment target
- 3
- Study locations
NCT02556918: Completed Phase 4 study of Hyperglycemia, sponsored by Emory University.
NCT02556918 is a Phase 4 study of Hyperglycemia that has completed, run by Emory University. The registered enrollment target is 202 participants, below the 874-participant average among 38 other Hyperglycemia trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02556918, a Phase 4 study of Hyperglycemia, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 202 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is effective in maintaining blood sugar control in patients with type 2 diabetes (T2D).
Primary Outcome
Number of patients with blood glucose (BG) levels greater than 180 mg/dl
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Insulin glargine
- DRUG Regular Human Insulin
- DRUG Supplemental insulin (Insulin lispro)
Study Locations (3)
Georgia
- Grady Health System - Atlanta
- Emory Univeristy Hospital Midtown - Atlanta
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-11-06 |
| Phase | Phase 4 |
What the finished NCT02556918 record still lists
NCT02556918 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 874-participant average among 38 other Hyperglycemia trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Hyperglycemia appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02556918 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02556918 about?
NCT02556918 is a clinical study titled "Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery". The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is effective in maintaining blood sugar control in patients with type 2 diabet...
What is the current status of trial NCT02556918?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 202 participants. The study started on 2016-01. Estimated completion is 2018-11-06.
What conditions does trial NCT02556918 study?
This clinical trial studies the following conditions: Hyperglycemia.
What interventions are being tested in trial NCT02556918?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Insulin glargine (DRUG), Regular Human Insulin (DRUG), Supplemental insulin (Insulin lispro) (DRUG).
Who is sponsoring clinical trial NCT02556918?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02556918 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02556918's enrollment target sits among peer trials
202 8th of 38 higher than 31 of 38 other Hyperglycemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperglycemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Zinc on Glucose Homeostasis
RECRUITING · Phase 4
-
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
COMPLETED · Phase 4
-
Diabetes in the Elderly: Prospective Study
COMPLETED · Phase 4
-
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
COMPLETED · Phase 4
-
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
COMPLETED · Phase 4
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia